Picture3.jpg
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
17. Juli 2023 16:15 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Picture3.jpg
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
11. Juli 2023 08:30 ET | Clearmind Medicine Inc.
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery...
Picture3.jpg
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
16. Juni 2023 09:05 ET | Clearmind Medicine Inc.
The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary...
Picture3.jpg
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
09. Juni 2023 09:30 ET | Clearmind Medicine Inc.
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...
Picture3.jpg
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
22. Mai 2023 08:30 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Picture3.jpg
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
19. Mai 2023 16:15 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...
Picture3.jpg
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
17. Mai 2023 09:00 ET | Clearmind Medicine Inc.
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, May 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND),...
Picture3.jpg
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
12. Mai 2023 09:00 ET | Clearmind Medicine Inc.
IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind...
Picture3.jpg
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
09. Mai 2023 16:15 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Picture3.jpg
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
08. Mai 2023 08:30 ET | Clearmind Medicine Inc.
Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome  Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....